

Extending Residence Time and Stability of Peptides by Protected Graft Copolymer (PGC) Excipient: GLP-I Example

Gerardo M. Castillo · Sandra Reichstetter · Elijah M. Bolotin

Received: 6 May 2011 / Accepted: 14 July 2011
© Springer Science+Business Media, LLC 2011

ABSTRACT

Purpose To determine whether a Protected Graft Copolymer (PGC) containing fatty acid can be used as a stabilizing excipient for GLP-I and whether PGC/GLP-I given once a week can be an effective treatment for diabetes.

Methods To create a PGC excipient, polylysine was grafted with methoxypolyethyleneglycol and fatty acid at the epsilon amino groups. We performed evaluation of the binding of excipient to GLP-I, the DPP IV sensitivity of GLP-I formulated with PGC as the excipient, the *in vitro* bio-activity of excipient-formulated GLP-I, the *in vivo* pharmacokinetics of excipient-formulated GLP-I, and the efficacy of the excipient-formulated GLP-I in diabetic rats.

Results We showed reproducible synthesis of PGC excipient, high affinity binding of PGC to GLP-I, slowed protease degradation of excipient-formulated GLP-I, and that excipient-formulated GLP-I induced calcium influx in INS cells. Excipient-formulated GLP-I stays in the blood for at least 4 days. When excipient-formulated GLP-I was given subcutaneously once a week to diabetic ZDF rats, a significant reduction of HbA1c compared to control was observed. The reduction is similar to diabetic ZDF rats given exendin twice a day.

Conclusions PGC can be an ideal *in vivo* stabilizing excipient for biologically labile peptides.

KEY WORDS diabetes · glucagon like peptide · peptide excipient · protected graft copolymer

ABBREVIATIONS

DPP IV	dipeptidyl peptidase IV
GLP-I	Glucagon-like peptide-1
HbA1c	glycosylated hemoglobin
PEGylation	poly(ethylene glycol) conjugation
PGC	protected graft copolymer

INTRODUCTION

Incretins such as Glucagon-like peptide-1 and its mimetics are considered to be effective type 2 diabetic therapeutics (1–4). The Glucagon-like peptide-1 (GLP-1) possesses many glucoregulatory functions and ameliorates endocrine pancreatic functions by stimulating glucose-dependent insulin secretion, suppressing glucagon secretion, reducing gastric mobility and food intake, and stimulating pancreatic β -cell proliferation and/or neogenesis (3,4). The short biological half-life of GLP-1, due to enzymatic degradation by dipeptidyl peptidase IV (DPP IV), encouraged numerous researchers to focus on the development of DPP IV-resistant GLP-1 analogs, and these efforts resulted in the successful clinical application of exendin-4 from lizard venom (5–7). However, being a foreign peptide, antibody production was observed in a significant portion of patients using exendin-4 (8). Although the co-administration of exendin-4 with traditional hypoglycemic agents improved the anti-diabetic effects of treatment, such as decreased glycosylated hemoglobin (HbA1c) levels and body weights of type 2 diabetic patients, a strong demand exists for long-acting GLP-1 with improved therapeutic effects from extending the duration of actions (7,9,10). Furthermore, low molecular weight peptide incretins and their mimetics are eliminated by glomerular filtration and enzymatic

G. M. Castillo (✉) · S. Reichstetter · E. M. Bolotin (✉)
PharmalN Corporation
720 Broadway Suite 511
Seattle, Washington 98122, USA
e-mail: gcastillo@pharmain.com
e-mail: ebolotin@pharmain.com

degradation; for example, exendin-4 has an elimination half-life of only 2.4 h (11,12). To address this issue, researchers have focused on the development of long-acting incretins, their mimetics, or sustained delivery systems. Specific approaches target the prevention of rapid renal clearance by increasing the molecular size (13–17). The strategies adopted to date include modifications of GLP-1 receptor agonists by poly(ethylene glycol) conjugation, known as PEGylation (15–17), or chemical or genetic modifications with serum albumin (13,14). Other approaches involve the acylation of incretin (18) and its mimetics (9,19–21), allowing for albumin binding and preventing rapid kidney elimination. An approach using a sustained-release formulation of GLP-1 receptor agonist based on biodegradable microsphere technology is also being investigated in the context of long-acting anti-diabetics (10). A new approach is formulation of native GLP-1 in an affinity based polymeric carrier such as the protected graft copolymer (PGC) with an affinity for GLP-1 that is greater than the affinity of DPP IV for GLP-1, but less than the affinity of GLP-1 for its receptor.

In this study, we designed long-acting native GLP-1 for type 2 diabetic therapy. Specifically, we developed a PGC with a hydrophobic region made up of stearic acid covalently linked to a polymer backbone. This PGC has a dissociation constant (K_d) of 250 nM which is lower than the Michaelis-Menten constant (K_m) of DPP IV for GLP-1 (1–3 μ M) but greater than the K_d of GLP-1 to its receptor (1–2 nM). Because the formulation is affinity based, a decrease in free GLP-1 resulting from binding to its receptor or normal metabolism will result in the release of more GLP-1 from PGC. The PGC is made up of a 20 kDa polylysine backbone in which 50–55% of the epsilon amino groups are derivatized with 5 kDa PEG and the remaining amino groups are derivatized with stearic acid. The overall hydrodynamic diameter of this PGC is 20 nm, which allows trafficking from a subcutaneous site to the blood. We present data relating to the binding of native GLP-1 to PGC, protection of PGC-GLP-1 from DPP IV degradation, *in vitro* biological activity of PGC-GLP-1, extension of blood circulation half-life of PGC-GLP-1, and the ability of the PGC-GLP-1 formulation, administered once a week, to lower HbA1c levels in ZDF rats similar to the action of exendin-4 given twice a day.

MATERIALS AND METHODS

Materials and Animals

GLP-1, exendin-4 and N-hydroxysulfosuccinimide (NHSS) were purchased from ChemPep, Inc. (Miami, FL). The following were from Sigma-Aldrich (Saint Louis, MO)

irrespective of the original manufacturer: 20 kDa Polylysine (20PL; SAFC catalog #Q4926), N-hydroxysuccinimide (NHS), 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride (EDC), Dichloromethane (DCM), N,N-Diisopropylethylamine (DIPEA), and Porcine kidney DPP IV. Morpholino ethane sulfonate (MES) buffer and Dicyclohexylcarbodiimide (DCC) were from Thermo Scientific/Pierce (Rockford, IL). Filter papers, Chloroform, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, 10xPBS (1x is 137 mM NaCl, 2.7 mM KCl, 10 mM Phosphate) buffer and Stearic acid (C18; Alfa Aesar) were from Fisher Scientific (Pittsburgh, PA). Methoxy-polyethelenglycol-succinate (MPEG) was from Laysan Bio (Arab, AL). All chemical reagents for PGC synthesis, unless otherwise indicated, were of 95% purity or greater. The ELISA Kit for biologically active GLP-1 was purchased from Linco/Millipore Cat. # EGLP-35 K (Billerica, MA). Microcentrifuge filters with 100 kDa molecular weight cut-off (regenerated cellulose filter, YM-100) for separation of PGC-bound and free GLP-1 were from Millipore (Billerica, MA). HPLC Gel Permeation Columns (GPC) for hydrodynamic size determination of PGC (0.78×30 cm; G4000PWXL) were from Tosoh Bioscience (King of Prussia, PA). Globular protein standards of known hydrodynamic diameters were from Sigma-Aldrich (Saint Louis, MO). An additional HPLC Gel Permeation Column for determination of PGC binding to GLP-1 (0.78×30 cm; BioSEP S2000 column) plus a reverse phase column (Synergi 2.5 μ m Max, 0.4×2 cm) for quantification of GLP-1 were from Phenomenex (Torrance, CA). An Ultrafiltration cartridge (100 kDa MWCO; UFP-100-E-5A) was from GE Healthcare Life Sciences (Piscataway, NJ). Assay kits for blood glucose levels and Hemoglobin A1c (HbA1c) were from Bayer (Sunnyvale, CA). The Fura-2AM for Calcium influx assay was from Invitrogen (Carlsbad, CA). A stock of INS-1 cells was a gift from Dr. Paul Robertson (President of ADA). ZDF rats were from Charles River Laboratories (Wilmington, MA). All animals were cared for in accordance with the National Institute of Health (NIH) guidelines for the care and use of laboratory animals (NIH publication 85–23, revised 1985).

Preparation and Purification of PGC and PGC-C18

Poly-L-lysine (20PL), hydrobromide (21 μ mol or 1 g; Sigma, Average M_w =26 kDa; d.p.126) was dissolved in 25 ml of 1 M HEPES, pH 7.4. An aliquot of this solution was removed for NH₂-groups determination by TNBS titration (22) and found to be 2.6 mmol. Methoxy polyethylene glycol carboxymethyl (MPEG-CM; 10 g; M_w =5 kDa; 2 mmol; Laysan Bio) was dissolved in 25 ml of 10 mM MES pH=4.7 with 4 mmol NHSS, and, once dissolved, 6 mmol EDC was added while stirring. Activa-

tion was allowed to proceed for 20 min, and the activated MPEG-CM was added directly to the 20PL solution. The pH of the solution was adjusted to 7.7 using NaOH and stirred for 2 h at room temperature. An aliquot was taken, and amino groups were measured by TNBS and found to be 1.2 mmol, indicating 54% MPEG-CM saturation. The hydrodynamic diameter was determined by size exclusion chromatography using TosohG4000WXL (0.78×30 cm) and found to be 14.4 nm. The crude product (crude PGC) was lyophilized. The synthetic scheme for the preparation of PGC is presented in Fig. 1.

Stearyl-NHS (C18-NHS) was prepared by dissolving stearic acid (20 g or 71 mmol) in 115 ml chloroform at 55°C. NHS (8.3 g or 72 mmol) was dissolved in 42 ml THF and added to the stearic acid solution. DCC (11.6 ml or 72 mmol) was added and stirred for 2 h. The solution was cooled down on ice, and the precipitate (DCC-urea, unreacted fatty acid and NHS) was removed by filtration (Fisher filter paper P2). The filtrate containing C18-NHS was rotary evaporated and dissolved in 70°C isopropanol (500 ml), followed immediately by filtration (Fisher filter paper Q8). The filtrate remained clear initially and was allowed to crystallize overnight. The next day, C18-NHS crystals were collected by filtration (Fisher filter paper Q8) and dried.

Crude PGC-C18 was dissolved in ~100 ml DCM. The solution was vortexed and centrifuged for 12 min at max speed to remove precipitates. The precipitate was further washed with ~50 ml DCM. The supernatants were pooled, and the solid was discarded. C18-NHS (3.6 mmol; 3x molar excess over amino groups) in 20 ml DCM was added to the pooled supernatant with magnetic stirring. DIPEA (6 mmol; 5x molar excess over amino groups) was added and allowed to react for 4 h. Additional C18-NHS (3.6 mmol) was added and allowed

to react overnight. An aliquot was taken, dried, and dissolved in water for amino group analysis, and a trace amount (0.06 mmol) of total amino groups was indicated by TNBS assay. The reaction mixture was concentrated by rotary evaporation (bath temp=41°C) under vacuum to remove DCM/DIPEA until it formed a thick oil. The oil was dissolved in ethanol (~100 ml) followed by the addition of ~10 ml of water. The solution was filtered through glass-fiber filter (Fisher G6). The filtrate was loaded in a QuixStand™ benchtop system with a 100 kDa MWCO ultrafiltration cartridge (UFP-100-E-5A), concentrated to 100 ml, washed with 80% ethanol (13 volume changes) followed by water (10 volume changes). The retentate (PGC-C18) was collected, 0.2 um filtered (polysulfone filter, Nalgene, Rochester, NY) and lyophilized, yielding ~8 g. One mg/ml was analyzed and found to contain 7 nmol amino groups/mg with GPC (0.78×30 cm; G4000PWXL) retention time of 12.2 min (or approximately 18.6 nm diameter). The GPC column was calibrated using globular protein standards of known hydrodynamic diameters: bovine thyroglobulin, horse apoferritin, Catalase, yeast alcohol dehydrogenase, bovine serum albumin, and ribonuclease with hydrodynamic diameters of 17.10, 15.60, 10.44, 9.20, 7.11, and 3.28 nm, respectively. A regression line equation of the plot of square root of negative logKav values against known hydrodynamic diameters was used to obtain hydrodynamic diameters of the PGC.

Binding of GLP-1 to PGC-C18

Binding experiments were performed using a GPC column (0.78×30 cm; BioSEP S2000, Phenomenex) eluted with PBS at a flow rate of 1.5 ml/min. Under these conditions, PGC-C18 alone eluted at the Void volume (Vo), and




Fig. 1 Schematic illustration of synthetic scheme for PGC as described in the methods.

GLP-1 alone eluted at the Total volume (Vt). To qualitatively determine the GLP-1 bound to PGC-C18, varying concentrations of PGC-C18 (5, 10, 20 mg/ml; 50 μ l injection volume) alone were injected onto the column as blanks, and the same concentrations were injected in the presence of 2 mg/ml GLP-1. The chromatograms of the PGC-C18 blanks at 220 nm were subtracted from the chromatograms of the PGC-C18/GLP-1 mixture to accurately track the binding of GLP-1 to the carrier as GLP-1 moved to the V_o .

To determine the dissociation constant of GLP-1 to the PGC-C18 carrier, 5 mg of PGC-C18/tube was mixed with 0.50, 0.40, 0.30, 0.25, 0.20, 0.15, 0.10 mg of GLP-1 in 250 μ l of 100 mM HEPES buffer, pH 7.4. The samples were filtered using a 5 nm diameter cut-off centrifugal filter (100 kDa MWCO, regenerated cellulose filter, YM-100), and the filtrate containing free (unbound) GLP-1 (3297.7 Da; 1.6 nm diameter) was quantified by reverse phase HPLC (Synergi 2.5 μ m Max, 0.4 \times 2 cm) at a flow rate of 1.5 ml/min using a gradient of 0%B for 1 min and 25–50% B from 1–5 min, where A is 5% acetonitrile with 0.1% TFA and B is 100% acetonitrile with 0.1% TFA. The filter retentate containing bound GLP-1 was eluted twice with 100 μ l of 70% acetonitrile and diluted with water for reverse phase HPLC quantitation as above. The filter used does not bind GLP-1 (data not shown), and thus all GLP-1 retained by the filter is bound to the 350 kDa PGC-C18. The bound/free GLP-1 was plotted along the y-axis against bound GLP-1 (nM) along the x-axis. The slope of the graph (Scatchard plot) of bound/free on the y-axis and bound (nM) x-axis was taken as $-1/K_d$, where K_d is the dissociation constant. The capacity per PGC-C18 was taken as the x-intercept divided by molar concentration of the PGC-C18 used.

DPP IV Degradation of GLP-1 in the Presence or Absence of PGC or PGC-C18

To test the ability of PGC-C18 to protect GLP-1 from DPP IV degradation, 1 mg/ml of GLP-1 in PBS buffer, pH 7.4 was incubated with 1.25 mU/ml of DPP IV for 24 h at 37°C in the presence of 10 mg/ml PGC-C18 or 10 mg/ml PGC (Polylysine with PEG but without C18). Next, an equal volume of isopropyl alcohol was added to dissociate the GLP-1 from the PGC, and the solutions were filtered through the 100 kDa MWCO filter as above. The filtrates containing degraded and un-degraded GLP-1 were analyzed by reverse phase HPLC as above. DPP IV removes the N-terminus of GLP-1 containing histidine, and, under the acidic conditions of the HPLC column, the degradation product is more hydrophobic and is retained longer by the column (seen as a later eluting peak, 2.82 min *vs.* 2.70 min for intact GLP-1).

PGC-C18- GLP-1 Formulation Stimulated Ca Influx in INS-1 Cells

To determine whether formulated GLP-1 is still active, we performed a Ca influx assay in INS-1 cells. INS-1 cells are insulinoma cells expressing GLP-1 receptors. A calcium influx assay was used to confirm that the bound GLP-1 maintained its activity after formulation. For this assay, INS-1 cells were seeded in black 96-well plates at 200,000 cells per well in a buffered medium containing RPMI/10% FBS/11.1 mM glucose/10 mM HEPES, pH7.4/1 mM pyruvate/50 μ M 2-Mercaptoethanol. Cells were allowed to adhere overnight and then labeled by replacing the medium with 20 μ l of 5 μ g/ml Fura2 in PBS pH7.4/2% FBS/11.1 mM glucose; incubation for 2 h was followed by the addition of 180 μ l PBS pH7.4/2%FBS/11.1 mM glucose. Fluorescence (340ex/510em) was monitored using a BioScan Chameleon (Washington, DC), and after 10 s, free GLP-1 and PGC-C18-GLP-1 ($n=6$ each) was added to a final GLP-1 concentration of 30 nM, and monitoring was continued for 1 min. Prior to testing, ionomycin was used as a positive control to ensure that the cells were properly loaded with Fura2 and the Calcium influx could be properly detected under these conditions (not shown). For a control, an equivalent amount of PGC-C18 or PBS ($n=6$ each) was analyzed. The influx of calcium into the cells is reflected by an increase in fluorescence. The average of 6 tracings from each group was obtained.

Pharmacokinetic Profiles of GLP-1 and GLP-1 in PGC-C18

GLP-1 was formulated with or without 50x weight of PGC-C18 (2% loading) in saline and given subcutaneously at a dose of 1 mg GLP-1/kg in Sprague–Dawley rats ($n=10$). The rats were bled at 0, 1, 20 min, 1, 2, 6, 24, 48, 72, 96, and 144 h. To prevent further degradation of GLP-1, blood samples were collected in tubes containing DPP IV inhibitor that comes with the GLP-1 ELISA kit. The assay for blood GLP-1 was done using a sandwich-type GLP-1 ELISA kit that uses alkaline phosphatase and the MUP (methyl umbelliferyl phosphate) fluorogenic substrate. The assay was done according to the kit manufacturer's instructions.

Efficacy of PGC-C18 GLP-1 Formulation in Treatment of Type 2 Diabetes Animal Model

Zucker diabetic fatty (ZDF) rats were treated for 7 weeks ($n=10$ /group) with saline (daily), GLP-1 (1 mg/kg, 3x/week), exendin (3 μ g/kg, 2x/day), or PGC-C18-GLP-1 (1 mg/kg, 1x/week or 2x/week). The average starting HbA1c (average \pm standard deviation; $n=10$) at the beginning of the treatment (week 0) for saline group, exendin-4 group, PGC-C18 GLP-1 group 1x/week, and PGC-C18 GLP-1 group

2x/week were 7.7+/- 0.91, 7.5+/- 0.72, 9.5+/- 0.72, and 9.5+/- 0.94, respectively. The PGC-C18-GLP-1 formulation contained 1 mg GLP-1 per 50 mg of PGC-C18 (2% loading) in saline. The dosing of GLP-1 compared to exendin-4 was based on the fact that exendin-4 is 5000x more potent than GLP-1 (24); therefore, the total weekly dose for exendin-4 of 42 ug would have the equivalent biological activity of 210 mg GLP-1. When combined with PGC-C18, however, the GLP-1 dose to achieve the same biological activity was reduced by 210-fold. All treatments were given subcutaneously at the dorsal shoulder. HbA1c is a proxy for the average blood glucose level over the past 3–5 weeks and was measured using a HbA1c kit (A1Cnow) at 7 weeks.

Stability of PGC-C18-GLP-1 Formulation

To get a sense of the stability of GLP-1 formulation as a potential commercial product, we incubated lyophilized GLP-1 mixed with PGC-C18 at 1 to 50 w/w (GLP-1 to PGC-C18) ratio and GLP-1 alone. These were lyophilized in sterile water, and there was no salt or buffer in these lyophilized powders. We also incubated similar vials after reconstitution in sterile 100 mM glycine, pH 6.8, to obtain a final GLP-1 concentration of 2 mg/ml. These lyophilized powders and liquid solutions were incubated at 37°C, and aliquots were taken monthly for analysis of free GLP-1 and PGC-C18 bound GLP-1 by reverse phase HPLC as above. An increase in free GLP-1 (not bound to PGC-C18) without corresponding degradation with time is an indication of either a loss of GLP-1 secondary structure responsible for binding to PGC-C18 or a breakdown of the carrier. The stability study was stopped when a significant degradation (10%) of GLP-1 was observed based on the total area of GLP-1 peak (both PGC-C18 bound GLP-1 and free GLP-1).

RESULTS

Reproducibility of PGC-C18 Synthesis

Synthesis of several batches of PGC-C18 indicates good reproducibility. In Table 1 are the in-process quality control parameters that are measured to ensure reproducibility of PGC-C18 from batch to batch. This indicates that the synthesis of the carrier is reproducible at two batch sizes and the synthetic process is robust and can easily be transferred to a cGMP facility to produce sufficient material for clinical trials.

Binding of GLP-1 to PGC-C18

We used a gel permeation column (0.78 × 30 cm; BioSEP S2000 column) to initially determine the ability of PGC-C18 to bind GLP-1. Shown in Fig. 2 are chromatograms of GLP-1 samples in the absence or presence of various concentrations of PGC-C18. In this particular column, GLP-1 (mw=3 kDa) alone elutes at the column total volume (Vt), and the PGC-C18 (Mw=350 kDa) alone elutes at the void volume (Vo); the peaks for PGC-C18 alone were quantitatively subtracted from each of the chromatograms. As can be seen, as the GLP-1 weight decreases relative to PGC-C18 weight (40%, 20%, and 10% of PGC-C18 weight) or as the GLP-1 loading of the PGC-C18 decreases, more GLP-1 is seen at Vo indicating that GLP-1 binds to the carrier. This was confirmed by determination of Kd using a Scatchard plot. Figure 3 shows high affinity binding of GLP-1 to the PGC-C18 with a Kd of 248 nM and a capacity of 4–5 GLP-1 molecules per PGC-C18 molecule. In addition, there are some low affinity binding sites that can be observed with apparent

Table 1 Reproducibility of PGC-C18 Carriers

PGC-C18 Lot #	70510A	70510B	70613C
Polylysine degree of polymerization (average) (Polydispersity Mn/Mw)	115 (1.2)	115 (1.2)	115 (1.2)
% PEG Sat	54%	54%	55%
Carrier Retention Time Before Fatty acid Addition (min) using Tosoh GX4000XL (0.78 × 30 cm)	12.9	12.9	12.9
Size Diameter of PGC	14 nm	14 nm	14 nm
Carrier Retention Time After Fatty acid Addition (min) using Tosoh GX4000XL (0.78 × 30 cm)	12.16	12.22	12.03
Carrier Diameter of PGC-C18	19 nm	18 nm	19 nm
Yield (based on starting PEG plus Polylysine weight as 100%)	79%	81%	81%
Amount	8.9 g	9.2 g	4.5 g
NH2 left in Carrier (started at 3umol/mg PL;% +/- STD)	6 nmol/mg (4+/-2%)	8 nmol/mg (5.2+/-2%)	10 nmol/mg (6.6 +/- 2%)
GLP-1 loading test (%loaded +/- STD when GLP-1 at 2% of carrier weight was loaded in 10 mg/ml Carrier)	95.8 +/- 0.05	96.1 +/- 0.43	95.9 +/- 0.09
Lysine content by weight after complete acid digestion	4.96%	4.87%	4.82%




Fig. 2 Gel Permeation HPLC chromatograms showing the extent of binding of GLP-1 to various concentrations of PGC-C18 carrier. Four chromatograms monitored at 220 nm are shown. The corresponding PGC-C18 signal was already subtracted from each of the chromatograms of the PGC-C18-GLP-1 mixtures, leaving only the signal due to GLP-1. As the amount of PGC-C18 in the mixture was increased from 0 mg/mL through 5, 10, and 20 mg/ml, the relative amount of GLP-1 carried by PGC-C18 from the total column volume (V_{total}) to the Void volume (V_o) increases. Chromatograms also demonstrate the stability of the complex between GLP-1 and PGC-C18; during the passage of the PGC-C18-GLP-1 complex through the column (0.78×30 cm; BioSEP S2000 column), the complex undergoes several thousand re-equilibrations (equal to the number of theoretical plates) driven by the thermodynamic equilibrium defined by K_d . If the interaction is weak, no GLP-1 should be present in the column void volume. The fact that GLP-1 co-elutes with the carrier at the V_o indicates strong interaction.

K_d s of 3.7 and 33 μ M and capacities of 2 GLP-1 molecules per PGC-C18 molecule in both cases. It is possible that the overall GLP-1 binding observed in PGC-C18 carrier is an

average of many heterogeneous sites that range from very high affinity to low affinity, rather than a very distinct population of sites present in a polymeric structure. In both

Dissociation constant (K_d) of GLP1 to PGC-C18 Carrier as Determined by Scatchard Plot




Fig. 3 Scatchard plot of GLP-1 binding to PGC-C18 shows various affinities. In this particular experiment three K_d values (249 nM, 3.7 μ M, and 33 μ M) were calculated over three ranges of bound GLP-1 concentration. The % of GLP-1 bound to the carrier varies based on the available GLP-1. It is evident from this data that there is a range of interaction from high affinity (K_d of nM) to lower affinity interactions (K_d of μ M) between the carrier and PGC-C18 and that a PGC-C18 capacity for GLP-1 of up to 9 is attainable. Those sites with average K_d of 249 nM have a capacity of 4–5 GLP-1 (3 kDa) molecules per molecule of PGC-C18 (350 kDa). Those sites with K_d of 3.7 μ M have a capacity of 2 GLP-1 molecules per molecule of PGC-C18. Those sites with K_d of 33 μ M have a capacity of 2 GLP-1 molecules per molecule of PGC-C18. The K_d of the sites with the least affinity is very similar to the K_m of DPP IV to GLP-1 (36 μ M), indicating that this site may not be a good sequestering site to protect GLP-1 from the DPP IV enzyme. In this particular experiment, 500 μ L samples were prepared in triplicate containing 0 or 5.0 mg carrier with 0.10, 0.15, 0.20, 0.25, 0.30, 0.40, and 0.50 mg of GLP-1 in PBS, pH 7.35. These correspond to 2%, 3%, 4%, 5%, 6%, 8% and 10% loading relative to carrier weight, respectively. Sample chromatograms after treatment w/1.25 mU/ml DPP IV for 24 h.

the gel permeation column binding analysis and the filtration assay for bound and free GLP-1, no binding was observed with PGC without C18. This indicates that C18 is essential for GLP-1 binding to PGC-C18.

PGC-Hydrophobic Core (PGC-HC) Protects GLP-1 from Rapid DPP IV Digestion

Only the carrier containing C18 (which is essential for binding) would protect the GLP-1 from DPP IV degradation. This also indicates that binding of GLP-1 to PGC-C18 is essential for protection of GLP-1 from DPP IV digestion. *In vivo*, DPP IV is involved in glucose metabolism, with GLP-1 being one of its substrates. Figure 4 illustrates the ability of the carrier to protect GLP-1 from DPP IV degradation. DPP IV removes the N-terminus of GLP-1 containing histidine, and under the acidic conditions of the HPLC column, the degradation product is more hydrophobic and retained longer by the column (seen as a later eluting peak, 2.82 min *vs.* 2.70 min for intact GLP-1). The weight ratio of GLP-1 to PGC-C18 or PGC used in this experiment was 1:10, indicating that the PGC-C18 is fully saturated at high and low affinity sites. Without any carrier, 58+/-5% ($n=6$; presented as mean +/-SD) GLP-1 was degraded by 1.25 mU/mL DPP IV in 24 h. In the presence of the carrier PGC-C18, only 26+/-2% ($n=6$) of GLP-1

was degraded. A PGC without C18 fatty acid was used as a carrier control and showed similar results to the GLP-1 control with 58+/-8% ($n=6$) degradation. The K_m of DPP IV for GLP-1 is 36 μM (25), and the high affinity K_d of GLP-1 for the PGC-C18 carrier is 249 nM. In order for the DPP IV to function at maximum efficiency, the accessible or free GLP-1 concentrations need to be in the μM range, close to K_m . The capacity of the PGC-C18 for GLP-1 at the high affinity site is 4–5, indicating that if 100 mg PGC-C18 is mixed with 4–5 mg of GLP-1, the concentration of free GLP-1 on which DPP IV could act is in the 249 nM range, which will significantly decrease the efficiency of DPP IV to degrade GLP-1. Since all sites are saturated with GLP-1, including the low affinity sites, it is expected that free GLP-1 under these conditions will be higher than 249 nM, and the low affinity site K_d (3.7 and 33 μM) will initially determine the amount of free GLP-1. Once the amount of GLP-1 decreases such that the low affinity sites are empty, the concentration of free GLP-1 will be determined by the high affinity sites. The results presented in this figure show a certain level of degradation consistent with the presence of free GLP-1 on which the DPP IV can act, though not in a very efficient way. The presence of a low level of free GLP-1 is necessary and sufficient to saturate the GLP-1 receptors with K_d of 1–2 nM (26).




Fig. 4 PGC with C18 protects GLP-1 from rapid DPP IV digestion but not PGC without C18. HPLC profiles of GLP-1 after a 24-h digestion with 1.25 mU/ml of DPP IV at 37°C. It is clear that only the carrier containing C18 (which is essential for binding) protects GLP-1 from dipeptidyl peptidase-IV (DPP IV) degradation compared to the control without PGC. Without the carrier 58+/-5% ($n=6$) GLP-1 was degraded in 24 h. In the presence of the carrier PGC-C18, only 26+/-2% ($n=6$) of GLP-1 was degraded. A PGC without C18 fatty acid was used as a carrier control and showed similar results to the GLP-1 control with 58+/-8% ($n=6$) degradation. A 10x excess of PGC-C18 or PGC over GLP-1 by mass was used for this experiment. Typical formulation has 50-fold excess PGC over GLP-1, which will push equilibrium (Fig. 8) to much less free GLP-1, making it much less accessible to proteases.

PGC-C18- GLP-I Formulation Has Sufficient Free GLP-I to Stimulate Ca Influx in INS-1 Cells

In order to determine if the PGC-C18-GLP-1 formulation has sufficient free GLP-1 to be biologically active, we used INS-1 cells that express a GLP-1 receptor. A calcium influx assay was used to confirm that PGC-C18-formulated GLP-1 maintained its activity after formulation. Figure 5 shows that PGC-C18-formulated GLP-1 has a sufficient amount of free and conformationally active GLP-1 that can bind and stimulate GLP-1 receptors as evident from stimulation of calcium influx similar to unformulated GLP-1. Both PBS and PGC-C18 alone do not result in a significant increase in calcium influx. This clearly shows that the PGC-C18-GLP-1 formulation can stimulate GLP-1 receptors.

PGC-C18-GLP-I Formulation Has a Much Longer Blood Circulation Time

Due to the size of PGC-C18 (19 nm), GLP-1 bound to it will have an apparent size exceeding the glomerular filtration cut-off of 4 nm and therefore be expected to stay in circulation for a longer period of time. In addition, the PEG shielding the GLP-1 bound to PGC-C18 will allow a significant reduction in the ability of the reticuloendothelial system to clear the complex, contributing to the increase in blood circulation time of the complex. By administering the formulation with a hydrodynamic diameter of 19 nm

subcutaneously, the T_{max} in the blood will be delayed, further prolonging the blood circulation time of the complex. Because the complex acts as reservoir that releases GLP-1 based on the K_d , a more controlled exposure of the body to free GLP-1 is expected. Figure 6 is a representative profile of many pharmacokinetic (PK) studies of PGC-C18 formulations that we have done over the past four years, showing the total GLP-1 in the blood (both PGC-C18 bound and free). The ELISA kit has sufficient immobilized antibody to pull all the GLP-1 (bound and free) towards the antibody bound to the plate because the amount of PGC-C18 is quite low despite its high affinity. While unformulated GLP-1 is gone from the blood in a matter of a few minutes, GLP-1 formulated in PGC-C18 stays in the blood for at least 100 h, an ideal formulation for twice a week administration in rats. Because the nature of the formulation has two compartments (bound GLP-1 and free GLP-1) as well as another two compartments due to the subcutaneous administration (subcutaneous site and blood), the half-life expected for GLP-1 measured as total (as presented in Fig. 6) will not be first order, and thus a linear regression of the graph will not be meaningful even if started at the C_{max} .

PGC-C18 GLP-I Formulation Given Twice in Type 2 Diabetes Animal Model Treatment

Zucker diabetic fatty (ZDF) rats were treated in three different experiments for up to 7 weeks with PGC-C18-




Fig. 5 Calcium influx experiment in INS-1 cells indicates that GLP-1 formulated in PGC-C18 is biologically active. PBS, GLP-1, GLP-1 in PGC-C18, and PGC-C18 alone were applied to INS-1 cells at the 10 s time point, and the increase in fluorescence (mean \pm SEM) resulting from calcium influx into the cells was monitored. In this assay, INS-1 cells were seeded in black 96-well plates at 200,000 cells per well in a buffered medium containing RPMI/10%FBS/11.1 mM glucose/10 mM HEPES, pH7.4/1 mM pyruvate/50 μ M 2-Mercaptoethanol. Cells were allowed to adhere overnight and were then labeled by replacing the medium with 20 μ l of 5 μ g/ml Fura2AM in PBS pH7.4/2%FBS/11.1 mM glucose. Cells were exposed to this Fura2AM solution for 2 h followed by the addition of 180 μ l PBS solution (pH7.4/2%FBS/11.1 mM glucose) to dilute the Fura2AM that was not absorbed into the cell cytoplasm. Fluorescence (340ex/510em) was monitored and after 10 s free GLP-1, and GLP-1 formulated in PGC-C18 ($n=6$ each) were added to a final GLP-1 concentration of 30 nM (0.1 μ g/mL). The PGC-C18 formulated GLP-1 has a PGC-C18:GLP-1 weight ratio of 50:1, similar to that used in the animal efficacy study. For controls, PBS or an equivalent amount of PGC-C18 ($n=6$ each) was added instead of GLP-1. The influx of calcium into the cells is reflected by the increase of fluorescence, along the y-axis. There was no statistically significant difference in the fluorescence between the PBS and PGC-C18 groups, or between GLP-1 and PGC-C18:GLP-1 groups. When the PBS group was compared to PGC-C18:GLP-1 and GLP-1 alone group for the fluorescence measured after the 12 s time point (2 s after addition of the compounds), the p -values of t -tests were $p < 0.01$ and < 0.001 , respectively, indicating that both GLP-1 alone and GLP-1 formulated in PGC-C18 were biologically active.




Fig. 6 GLP-1 formulated in PGC-C18 has extended blood circulation time compared to GLP-1 alone. Shown are the levels of total serum GLP-1 as measured using an ELISA specific for active GLP-1 (mean \pm SD). Sprague–Dawley rats ($n = 10$) were given subcutaneous injections of 1 mg/kg of either GLP-1 alone or GLP-1 formulated in PGC-C18. The GLP-1 formulated in PGC-C18 is at 2% loading or the ratio of GLP-1:PGC-C18 by weight is 1:50. The GLP-1 ELISA kit is a sandwich-type that uses alkaline phosphatase and the fluorogenic substrate MUP (methyl umbelliferyl phosphate).

formulated GLP-1 at 2% loading (1:50 w/w; GLP-1:PGC-C18). Figure 7 shows HbA1c values from week seven in ZDF rats ($n = 10$) using 1 mg/kg dose and various frequencies. All treatments were given subcutaneously. Free GLP-1 was given at 1 mg/kg three times/week and exendin-4 BID 3 μ g/kg twice daily. All treatment groups are significantly different ($P < 0.05$) from the control group. It is interesting that the group given unformulated GLP-1 at dose 1 mg/kg 3x a week is not significantly less effective in reducing HbA1c than those given exendin-4 twice a day. This may be because the frequency and dose estimation based on potency of exendin-4 (24) relative to GLP-1 may not have been properly matched. It is clear; however, that once-a-week administration of GLP-1 in PGC-C18 is as effective as twice-a-day administration of exendin-4. There were 98 injections of exendin-4 compared to 7 injections of

GLP-1 over 49 days, giving the GLP-1 in PGC-C18 a potential advantage in terms of convenience. Further, twice-a-week administration of GLP-1 in PGC-C18 showed a significantly lower HbA1c at week seven than the group that received the twice-a-day injection of exendin-4 ($P < 0.005$). HbA1c is a proxy for the average blood glucose level over the previous 3–5 weeks.

Stability PGC-C18 GLP-1 Formulation at 37°C

In order to determine the potential commercial use of the PGC-C18 formulation, we determined the stability at 37°C. We choose 37°C to force a rapid degradation of the formulation under worse conditions than the sample would likely encounter to ensure that, under mild conditions such as room temperature or refrigeration at 4°C,




Fig. 7 GLP-1 formulated in PGC-C18 is effective in improving HbA1c level in ZDF rats. Shown are HbA1c values (\pm standard deviation) in ZDF rats ($n = 10$) after 7 weeks of treatment. The Saline control group received once-a-day subcutaneous injections over 7 weeks. Exendin-4 2x/day group received twice-a-day subcutaneous injection, or 98 injections of exendin-4, at 3 μ g/kg over 7 weeks. The 1x/week GLP-1 group received once-a-week subcutaneous injections of 1 mg/Kg of GLP-1 formulated in PGC-C18 or a total of 7 injections over 7 weeks. The 2x/week GLP-1 group received twice a week subcutaneous injections of 1 mg/Kg of GLP-1 formulated in PGC-C18 or a total of 14 injections over 7 weeks. The GLP-1 formulated in PGC-C18 was at 2% loading or the ratio of GLP-1:PGC-C18 by weight is 1:50. The unformulated GLP-1 group received three-times-a-week subcutaneous injections over 7 weeks (data not shown, not statistically significant from exendin-4 2x/day). HbA1c is a proxy for the average blood glucose level over the previous 3–5 weeks.

we would be confident that the formulation would be stable. The stability was measured based on the total amount of intact GLP-1 and the amount of free and PGC-C18 bound GLP-1 by reversed phase HPLC. A 10% decrease in total GLP-1 in the formulation was considered degraded. Without PGC-C18, greater than 10% of GLP-1 was broken down within a month, while the formulation PGC/GLP-1 was stable for 1 month, both in liquid. Analysis at two months of the liquid formulations showed a decrease in the total GLP-1 peak (bound and unbound) of greater than 10% and an increase in the free GLP-1 from less than 5% to 50%. In contrast, the lyophilized formulation PGC/GLP-1 was stable for 10 months at 37°C: analysis at 11 months showed a decrease in total GLP-1 peak (bound and unbound) of greater than 10% and an increase in the free GLP-1 from less than 5% to 10% and at 12 months the free GLP-1 was 18.5%. This study indicates that a relatively stable formulation of PGC/GLP-1 is possible.

DISCUSSION

Type 2 diabetes is a chronic and progressive metabolic disease characterized by progressive hyperglycemia followed by dysfunctional insulin secretion and/or its impaired utilization. Although many commercially available hypoglycemic agents have been widely utilized to achieve glycemic control, strong demand still exists for therapies that improve glycemic control and maintain or improve pancreatic endocrine function (4,6). Enhanced GLP-1 receptor activation is one of various therapeutic targets that are considered to be most effective because of the multiple antidiabetic effects of GLP-1 and its receptor agonists (1–4). Because of a very short blood half-life of native GLP-1, a search for a more stable agonist of GLP-1 resulted in the successful clinical application of exendin-4 for antidiabetic therapy (6,7,27). Because exendin-4 is administered twice a day, further efforts to develop longer-acting GLP-1 receptor agonists with improved therapeutic efficacies continue, using various chemical conjugations such as PEGylation or acylation, physical entrapment into sustained delivery systems, and genetic approaches such as albumin-based fusion protein (13–17,19–21). All these approaches to increase blood half-life and decrease frequency of administration involved chemical modification of native GLP-1 or used analogs of GLP-1 (such as exendin-4) that may potentially induce a neutralizing antibody response upon chronic use by diabetic patients (12). In this study, we developed an excipient of native GLP-1 by simply conjugating stearic acid to PGC resulting in PGC-C18 that has high affinity for native unmodified GLP-1. This PGC-C18 binds GLP-1 in an affinity-based manner and maintains a small amount of free

GLP-1. When free GLP-1 binds to a receptor or is metabolized, the resulting decrease in free GLP-1 will trigger release of more GLP-1 from the excipient in a manner driven by K_d . Such a mechanism will, in principle, maintain a relatively constant level of free GLP-1 in the blood until the GLP-1 in the PGC-C18 reservoir is depleted. This is illustrated in Fig. 8.

Because the PGC used in this study has fatty acids and PEG, one would suspect that this structure would form a supramolecular structure, such as a micelle, in a water environment. Although this is true if the weight ratio of PEG to fatty acid in the molecule is below 15, it is not necessarily true when the PEG fatty acid ratio is above 15 (data not shown). The PEG to fatty acid ratio of the PGC used here is 21, and this composition does not elute at the void volume when run on gel permeation chromatography with aqueous solvent as mobile phase (see [Materials and Methods](#) section), indicating no micelle or other supramolecular structures formation. In addition, the solution of PGC appears clear even at 100 mg/ml, prior to a concentration-dependent increase in viscosity. However, PGC with a PEG to fatty acid ratio below 15 not only shows cloudiness at 100 mg/ml when dissolved in water but also elutes at the void volume on the gel permeation column with a molecular weight cut-off of greater than one million (data not shown). This is the result of our investigation of various PGC compositions that range in PEG to fatty acid weight ratio from 1.76 to 43. In fact, elution at the void volume on gel permeation chromatography only occurs at a PEG to fatty acid ratio of 15 and below. The design of PGC specifically avoids supramolecular structure formation by the absence of a hydrophobic “end” in the three-dimensional structure of the molecule. Without this hydrophobic end, formation of a supramolecular structure in water would theoretically be avoided. The step that prevents formation of the hydrophobic end is the addition of PEG where a statistical reaction puts PEG in a random order that allows an average distribution of PEG along the polylysine chain with no clustering of PEG at either end of the polylysine. Because PEG provides steric hindrance between the core of PGC and large molecules, such as very large proteins and other PGC molecules, such supramolecular structure formation was avoided despite the addition of hydrophobic moieties at the core of PGC. This can only be possible if there are sufficient PEG molecules on the polylysine backbone, and this limit was determined to be a ratio of PEG to fatty acid of greater than 15.

This technology is applicable to peptides that have significant hydrophobic domains or can assume a more hydrophobic alpha-helical conformation such as GLP-1 (28). When heated to 50°C, GLP-1 at 1 mg/ml in neutral solution is quite clear, but turns cloudy and less soluble as it cools down to room temperature. We believe this change is




Fig. 8 Schematic illustration of the equilibrium of free and PGC-C18 bound drugs. PGC-C18 is comprised of a polylysine backbone (dark wavy line at the center) where approximately all other epsilon amino groups are derivatized with methoxypolyethylene glycol or MPEG (dotted wavy lines) and the remaining epsilon amino groups are derivatized with stearic acid (dark blue oval shading) that provides sites, perhaps together with MPEG, for GLP-1 (small light blue circles, not to scale) to interact. The interaction can be defined by a thermodynamic equilibrium where free GLP-1 [free drug] is determined by experimentally measurable dissociation constant or K_d . In the present study, the PGC-C18 was used as an excipient for native GLP-1 such that it maintains a small amount of free GLP-1. When free GLP-1 binds to receptors or is metabolized, the resulting decrease in free GLP-1 will trigger release of more GLP-1 from the excipient in a manner driven by K_d . In principle, such a mechanism will maintain a relatively constant level of free GLP-1 in the blood until the GLP-1 in the PGC-C18 reservoir is depleted.

associated with the formation of the alpha helix and is also responsible for efficient binding of GLP-1 to the PGC-C18 excipient (Figs. 2 and 3). The Scatchard plot indicated that when PGC-C18 is fully saturated it can bind up to 9 GLP-1 molecules with four of those being low affinity sites that have K_d of 3–33 μM . Because the K_m of the DPP IV for GLP-1 (36 μM) is only slightly above the low affinity site range, fully saturating the PGC-C18 will offer limited protection to half of the GLP-1 loaded onto PGC-C18. Therefore, the ideal formulation will be 4–5 GLP-1 molecules per PGC-C18 molecule to ensure that mainly high affinity sites are occupied. Because each PGC-C18 molecule has an average of 65 units of 5 kDa MPEG molecules linked to the epsilon amino groups of polylysine in a random or statistical distribution, there will be significant shielding of the C18 moieties that are also linked to the remaining epsilon amino groups of polylysine. The C18 in PGC is a necessary component for binding of GLP-1, so the GLP-1 must interact close to the polylysine backbone where the C18 is attached, allowing for the MPEG moiety (3.5 nm hydrodynamic diameter) to partially shield the GLP-1 (2 nm hydrodynamic diameter) from its surroundings including DPP IV (Fig. 4). Since the bound GLP-1 will not be expected to bind to GLP-1 receptors because of the shielding, the question is whether the free GLP-1 concentration, provided by the K_d force of the equilibrium, is sufficient to bind and stimulate to GLP-1 receptor. Figure 5 indicates that the free GLP-1 in PGC-C18 formulation is active and can stimulate GLP-1 receptors. In principle, for the affinity-based GLP-1 delivery system to work as intended, the K_d of PGC-C18 for GLP-1 must be smaller than the K_m of DPP IV for GLP-1 but greater than the K_d of GLP-1 for its target receptor. If this is satisfied, then the concentration of free

GLP-1 will be too low for DPP IV to function efficiently, but more than enough to saturate the GLP-1 receptors.

There are other features of PGC-C18 that make it an ideal peptide drug delivery system. In this particular example, PGC-C18 has a hydrodynamic radius of 20 nm. The filtration cut-off of the kidney glomerulus is 4 nm; therefore, anything bound to the PGC-C18 will not be immediately flushed out of the kidneys. In addition, the exterior portion of PGC-C18 is mostly MPEG, which significantly slows down the ability of the reticuloendothelial system (29) to clear the complex from the circulation. This is consistent with the blood circulation half-life of FITC-labeled PGC-C18 in rats of 39 h (not shown) and, when administered subcutaneously, a T_{max} of approximately 50 h. Therefore, when administered subcutaneously, the PGC-C18 will have a blood residence time of at least 89 h (T_{max} + half-life). The PK data presented in Fig. 6 indicates that the blood residence time of GLP-1 from the PGC-C18 formulation is consistent with a PGC-C18-GLP-1 complex present in the blood because without PGC-C18 such GLP-1 level in the blood is not observed. Further, we know that PGC-C18 travels from the subcutaneous site to the blood based on a study of FITC-labeled PGC-C18 administered subcutaneously. In addition, filtration of serum using 100 kDa cut-off membrane (see [Materials and Methods](#) section) indicated that 90% of GLP-1 observed in serum is associated with high molecular weight molecules (not shown), presumably the PGC-C18 because this was not observed in serum from animals given only GLP-1. Another feature of PGC is its ability to passively accumulate in areas of increased vascular permeability such as inflammation and cancer. This is known as the enhanced permeability and retention (EPR) effect and is a function of the size of the nanocarrier (ideally 15–100 nm). Passive

accumulation of PGC using EPR has been shown in an inflamed pancreas in a diabetes model (30), thus allowing for an increase in local concentrations of GLP-1 at one of the sites of GLP-1 action.

Because Type 2 diabetes will require chronic administration of GLP-1, ideally we would want the PGC-C18 to be cleared from circulation prior to the next administration. The PGC-C18-GLP-1 can be administered in diabetic ZDF rats once a week or twice a week and be effective in improving HbA1c, comparable to or even more effective than exendin-4 given twice a day (Fig. 7). Because the blood circulation time of the PGC-C18 excipient is about 4 days in rats, a twice-a-week administration is possible without accumulation of PGC-C18 over time. Because humans have a different metabolic rate, dosing in humans needs to be investigated in the future. In addition to accumulation, the question of PGC-C18 toxicity must be clarified for any formulation that will use the PGC-C18 excipient. To this end, we have given mice ($n=10$) PGC-C18 (0.5 g/Kg) every other day for 8 weeks, and we did not observe any behavioral and physical (weight) abnormalities over the test period. After 8 weeks, no histological abnormalities were observed upon examination of H&E stained sections of liver, kidney and spleen (not shown). When mice were given 1 g/kg every other day, the normal weight gain stopped, compared to control, indicating that 1 g/kg is not tolerated in mice. When the 1 g/kg treatment was stopped, weight gain resumed within 3 days, indicating that PGC-C18 can be metabolized rapidly. The expected amount of PGC-C18 that will be given to a human patient is likely to be less than 10 mg/kg every other week or even once a week. Typical pegylation of protein uses molecular weights of PEG of 20 kDa or greater to overcome rapid kidney elimination, and this has been documented to accumulate over time (23). In contrast, PGC-C18 has 5 kDa PEG that can be flushed out of the kidney once hydrolyzed by enzymes from the PGC. The fatty acid is likely to be hydrolyzed by fatty acyl amide hydrolase, and the product fatty acid can be utilized by the body for fuel. The backbone polylysine can be hydrolyzed into individual amino acids. Although polylysine is toxic, due to its polycationic property that is disruptive to cell membranes and lysosomal pH, the polylysine makes up only 5% by weight of the PGC, so it is not likely to present as a highly concentrated polycation because the metabolism is expected to be gradual and non-localized to a single organ.

The synthesis of PGC-C18 is straightforward and begins with conjugation of MPEG to polylysine in a water-based reaction, making the complex soluble in both water and organic solvents. In order to add fatty acid, the reaction mixture was lyophilized followed by acylation in organic solvent. No chemical modification of native GLP-1 is needed to make the final formulation. The process is

reproducible with a yield of 70-80% of the starting PEG and polylysine weight (Table I). In summary, the present study suggests PGC-C18 is a powerful excipient that can prolong the half-life of GLP-1 by at least 1000-fold, potentially allowing for twice-a-week or even once-a-week administration in humans. The native GLP-1 formulated in PGC-C18 has a well-preserved biological activity as well as protracted pharmacokinetic and anti-diabetic characteristics similar to more frequently administered exendin-4.

CONCLUSION

Protected Graft Copolymer can prolong the blood residence time of GLP-1 by at least 1,000-fold and can be an ideal *in vivo* stabilizing excipient for other biologically labile peptides.

ACKNOWLEDGMENTS & DISCLOSURES

This work was supported by the SBIR Grant #DK069727 from National Institute of Diabetes and Digestive and Kidney diseases of the National Institute of Health. The authors thank Ms. Cynthia Jones, Ms. Akiko Nishimoto-Ashfield, and Ms. Marisa Robinson for assistance with the manuscript.

REFERENCES

1. Drucker DJ. The role of gut hormones in glucose homeostasis. *J Clin Invest.* 2007;117(1):24–32.
2. Kieffer TJ, Habener JF. The glucagon-like peptides. *Endocr Rev.* 1999;20(6):876–913.
3. Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. *Diabetes Metab Res Rev.* 2005;21(2):91–117.
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet.* 2006;368(9548):1696–705.
5. Eng J, Yu J, Rattan S, Yalow RS. Isolation and amino acid sequences of opossum vasoactive intestinal polypeptide and cholecystokinin octapeptide. *Proc Natl Acad Sci USA.* 1992;89(5):1809–11.
6. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 *in vitro* and *in vivo* by dipeptidyl peptidase IV. *Endocrinology.* 1995;136(8):3585–96.
7. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, *et al.* Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care.* 2005;28(5):1083–91.
8. Amylin Pharmaceuticals. http://www.rxlist.com/cgi/generic4/byetta_ad.htm. 2008.
9. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, *et al.* Liraglutide once a day *versus* exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet.* 2009;374(9683):39–47.

10. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, *et al.* Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care.* 2007;30(6):1487–93.
11. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. *Diabetologia.* 2006;49(4):706–12.
12. BYETTA. prescribing information [article online, revised june 2008], URL: <http://pi.lilly.com/us/byetta-pi.pdf>.
13. Huang YS, Chen Z, Chen YQ, Ma GC, Shan JF, Liu W, *et al.* Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in *Pichia pastoris*. *J Pept Sci.* 2008;14(5):588–95.
14. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, *et al.* Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor *in vivo*. *Diabetes.* 2003;52(3):751–9.
15. Lee S, Youn YS, Lee SH, Byun Y, Lee KC. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. *Diabetologia.* 2006;49(7):1608–11.
16. Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, *et al.* Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. *J Biol Chem.* 2006;281(18):12506–15.
17. Zhou J, Cai ZH, Li L, Kou C, Gao YF. Preparation and PEGylation of exendin-4 peptide secreted from yeast *Pichia pastoris*. *Eur J Pharm Biopharm.* 2009;72(2):412–7.
18. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. *J Control Release.* 2010;144(1):10–6.
19. Irwin N, O'Harte FP, Gault VA, Green BD, Greer B, Harriott P, *et al.* GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. *J Med Chem.* 2006;49(3):1047–54.
20. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thogersen H, Wilken M, *et al.* Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. *J Med Chem.* 2007;50(24):6126–32.
21. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, *et al.* The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. *Am J Physiol Endocrinol Metab.* 2002;283(4):E745–52.
22. Spadaro AC, Draghetta W, Del Lamma SN, Camargo AC, Greene LJ. A convenient manual trinitrobenzenesulfonic acid method for monitoring amino acids and peptides in chromatographic column effluents. *Anal Biochem.* 1979;96(2):317–21.
23. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. *Toxicol Sci.* 1998;42(2):152–7.
24. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, *et al.* Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (*Macaca mulatta*). *Diabetes.* 1999;48(5):1026–34.
25. Lambeir AM, Proost P, Scharpe S, De Meester I. A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, *in vitro*. *Biochem Pharmacol.* 2002;64(12):1753–6.
26. Crespel A, De Boisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like peptide-1-(7–36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. *Endocrinology.* 1996;137(9):3674–80.
27. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from *Heloderma suspectum* venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. *J Biol Chem.* 1992;267(11):7402–5.
28. Al-Sabah S, Donnelly D. The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists. *Protein Pept Lett.* 2004;11(1):9–14.
29. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. *Adv Drug Deliv Rev.* 2002;54(4):459–76.
30. Medarova Z, Castillo G, Dai G, Bolotin E, Bogdanov A, Moore A. Noninvasive magnetic resonance imaging of microvascular changes in type 1 diabetes. *Diabetes.* 2007;56(11):2677–82.